StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) stock

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$16.47−0.80 (-4.63%)

Close on Nov 17, 2026Market cap $3.61BP/E –Yield –

Relay Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Relay Therapeutics's price to sales ratio was 416.4× on Nov 11, 2026, against 163.6× a year earlier. Over the last 2 years it ranged from 37.8× to 416.4×, with a median of 116.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026416.4×+241.6
2025Dec 31, 2025174.8×+130.6
2024Jan 31, 202444.2×−8.4
2023Dec 29, 202352.6×–

More Relay Therapeutics figures

See a number that looks wrong?